Company

Seres

Seres Therapeutics

MCRB pharma USA

Quick answer

Seres is a pharma company (MCRB) headquartered in CAMBRIDGE, MA, USA with 8 tracked pipeline programs.

Pipeline (8)

SER-109

Clostridioides Difficile Infection

Phase 3 · mab · completed

1 trials project

SER-109

Clostridium Difficile Infection

Phase 3 · mab · completed

1 trials project

SER-109

Clostridium Difficile

Phase 2 · small_molecule · completed

1 trials project

Vancomycin Pre-Treatment

Ulcerative Colitis

Phase 2 · small_molecule · terminated

1 trials project

Placebo for antibiotic

Metastatic Melanoma

Phase 1 · small_molecule · completed

1 trials project

SER-262

Clostridium Difficile Infection

Phase 1 · small_molecule · completed

1 trials project

SER-287

Ulcerative Colitis

Phase 1 · small_molecule · completed

1 trials project

Vancomycin Pre-Treatment

Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1 · small_molecule · completed

Patents (8)

US 12409197

Synergistic bacterial compositions and methods of production and use thereof

Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12214002

Compositions and methods for treating antibiotic resistance

Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12083151

Synergistic bacterial compositions and methods of production and use thereof

Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11918612

Synergistic bacterial compositions and methods of production and use thereof

Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11730775

Methods for treatment of Clostridium difficile infection or recurrence or sympto

Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11701394

Compositions and methods for treating cholestatic disease

Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11666612

Network-based microbial compositions and methods

Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11464812

Synergistic bacterial compositions and methods of production and use thereof

Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

Data sources & disclaimer

This profile compiles public regulatory and patent records for informational use by pharmaceutical professionals. It is not medical advice, not investment advice, and not an official FDA, EMA, USPTO, SEC, or NIH record. NovaPharmaNews does not represent any manufacturer, sponsor, or regulator unless explicitly stated in a separate agreement.

Patent expiry and loss-of-exclusivity dates may be estimates when derived from grant date or bulk patent metadata. Confirm material dates against the USPTO, FDA Orange Book, or counsel before contractual or regulatory decisions.

Verify critical facts using the primary sources below. See our data sources policy (methodology) and privacy policy.

Last data refresh: May 23, 2026